Skip to main content
. 2024 Sep;24(9):1025–1036. doi: 10.1016/S1473-3099(24)00179-8

Figure 5.

Figure 5

Cumulative incidence (A) and vaccine efficacy (B) against the first new genotypic infection between months 2·5–14·0 for the pooled R012-14, R012-20, and Fx012-14 vs the control regimen in the per-protocol set by baseline malaria infection status while adjusting for M2-FOI

M2-FOI=number of new infections detected after the first vaccination visit and by the month 2 visit. PYR=person-year at risk.